Dormotech shares the release of a compelling expert highlight interview featuring Dr. Meir Kryger, Emeritus Professor at Yale School of Medicine. In this exclusive discussion, Dr. Kryger, a revered figure in the sleep industry who has been involved in sleep medicine since 1974, shares his unique perspective on the transformative […]
Sleep Apnea
Patient Primer – Oral Appliance Therapy for Sleep Apnea
If your dentist or sleep physician has recommended oral appliance therapy to treat your obstructive sleep apnea (OSA), you might be wondering how it works. This guide walks you through the basics so you’ll know what to expect and how to get the best results. What Is a Mandibular Advancement […]
Nyxoah Receives FDA Approval for Genio System for Treatment of OSA
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system (hypoglossal nerve stimulation) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is […]
Navigating Insurance and Reimbursement
Insurance coverage and reimbursement for home sleep testing (HST) devices have improved in leaps and bounds over the last two decades, but unfortunately, denials and delays in care remain far too common. For many providers, figuring out a way forward can feel like navigating a labyrinth of policies and red […]
Dormotech Highlights the Critical Need for Early Pediatric Sleep Apnea Diagnosis with Insights from Dr. Asher Tal
Dormotech, a leader in advancing sleep diagnostics through innovative, clinically validated solutions, emphasized the urgent need for early and accessible diagnosis of sleep disorders in children. This critical focus echoes the profound insights shared by globally respected pediatric sleep medicine expert, Dr. Asher Tal. In an in-depth interview with Dormotech, […]
Positive Topline Results from Second Phase 3 Trial of First OSA Pill
Apnimed, Inc. has announced positive topline results from its second pivotal Phase 3 clinical trial of Apnimed’s lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg). LunAIRo was a 12-month study that evaluated the efficacy and safety of AD109 in adults with mild, moderate and severe OSA, across a wide range of weight […]
Home Sleep Testing – No Business for Dentists?
Sleep apnea is a widespread sleep disorder affecting millions of Americans, yet many cases remain undiagnosed and untreated. Although the practice of screening patients with a home sleep test device by dentists is highly debated, as a board-certified sleep physician I firmly believe that dentists can play a crucial role […]
Sleep Bruxism and OSA
Are We Truly Open to Change in the Approach to OSA?
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
EnsoData partners with ABM to add Positional Data to EnsoSleep PPG
EnsoData, a leader in healthcare AI technology, is partnering with Advanced Brain Monitoring (ABM) to add position data captured by ABM’s Night Shift sleep positioner into the FDA-cleared EnsoSleep PPG home sleep test (HST). Adding positional data to EnsoSleep PPG offers providers accurate supine AHI severity insights, leading to better […]













